Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT02327442
Overview
The purpose of this study is to assess the safety, biodistribution, dosimetric properties of the positron emission tomography (PET) radiopharmaceutical agent 68Ga-NOTA-NFB. To preliminarily evaluate its application in glioma diagnosis. To assess the application of 68Ga-NOTA-NFB PET/CT in the evaluation of the neoadjuvant chemotherapy in patients with breast cancer before and after the therapy.
Sponsor
Xijing Hospital
Contacts
Jing Wang, Doctor (CONTACT)
wangjing@fmmu.edu.cn
86-29-84775449
Jing Wang, Doctor (STUDY_DIRECTOR)
Zhe Wang, Doctor (CONTACT)
dadaxueshan@163.com
86-29-84771048
ClinicalTrials.gov
NCT02327442Drug / Compound
Help us improve your experience